Brentuximab a novel antibody therapy: real‐world use confirms efficacy and tolerability for CD30‐positive cutaneous lymphoma
Brentuximab vedotin
Tolerability
Cutaneous T-cell lymphoma
DOI:
10.1111/bjd.18535
Publication Date:
2019-09-17T04:44:55Z
AUTHORS (8)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (7)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....